Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 0.66 |
| ▸ | HTR2A | P28223 | 10/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6152090 | 0.85 | SLC6A4 (0.66) | SLC6A4HTR2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL20852556 | 0.84 | SLC6A4 (0.73) | SLC6A4HTR2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL3130662 | 0.84 | MCL1 (0.53) | SLC6A4HTR2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL5546503 | 0.83 | SLC6A4 (0.70) | SLC6A4HTR2ASLC6A2SLC6A3MEN1 | |
| SCHEMBL3134684 | 0.82 | SLC6A4 (0.75) | SLC6A4HTR2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL19361290 | 0.81 | SLC6A4 (0.73) | SLC6A4HTR2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL19361237 | 0.80 | SLC6A4 (0.71) | SLC6A4HTR2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL6947509 | 0.80 | SLC6A4 (0.71) | SLC6A4HTR2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL6151742 | 0.78 | SLC6A4 (0.64) | SLC6A4HTR2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL6152176 | 0.77 | SLC6A4 (0.68) | SLC6A4HTR2ASLC6A2SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268396-B1 | DIPHENYL ETHER COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2005-07-20 | — | — | EP | disclosed |
| US-6448293-B1 | TREATMENT OR PREVENTION OF A DISORDER IN WHICH THE REGULATION OF MONOAMINE TRANSPORTER FUNCTION IS IMPLICATED, SUCH AS PREMATURE EJACULATION. | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| US-20020052395-A1 | Diphenyl ether compounds useful in therapy | ANDREWS MARK DAVID (GB) | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052395-A1 | Diphenyl ether compounds useful in therapy | CBR1, OGFR, CBR3 | SLC6A4 2002/4885HTR2A 1502/4885SLC6A2 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.